612 related articles for article (PubMed ID: 26100921)
1. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
2. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
3. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
Kim JH; Excler JL; Michael NL
Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
[TBL] [Abstract][Full Text] [Related]
4. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
5. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
6. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
7. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
8. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.
Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K
Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388
[TBL] [Abstract][Full Text] [Related]
9. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
10. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
12. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
[TBL] [Abstract][Full Text] [Related]
15. Novel directions in HIV-1 vaccines revealed from clinical trials.
Excler JL; Tomaras GD; Russell ND
Curr Opin HIV AIDS; 2013 Sep; 8(5):421-31. PubMed ID: 23743791
[TBL] [Abstract][Full Text] [Related]
16. Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
Haynes BF; Gilbert PB; McElrath MJ; Zolla-Pazner S; Tomaras GD; Alam SM; Evans DT; Montefiori DC; Karnasuta C; Sutthent R; Liao HX; DeVico AL; Lewis GK; Williams C; Pinter A; Fong Y; Janes H; DeCamp A; Huang Y; Rao M; Billings E; Karasavvas N; Robb ML; Ngauy V; de Souza MS; Paris R; Ferrari G; Bailer RT; Soderberg KA; Andrews C; Berman PW; Frahm N; De Rosa SC; Alpert MD; Yates NL; Shen X; Koup RA; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Michael NL; Kim JH
N Engl J Med; 2012 Apr; 366(14):1275-86. PubMed ID: 22475592
[TBL] [Abstract][Full Text] [Related]
17. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
[TBL] [Abstract][Full Text] [Related]
18. Immune Correlates of Disease Progression in Linked HIV-1 Infection.
Tuen M; Bimela JS; Banin AN; Ding S; Harkins GW; Weiss S; Itri V; Durham AR; Porcella SF; Soni S; Mayr L; Meli J; Torimiro JN; Tongo M; Wang X; Kong XP; NĂ¡das A; Kaufmann DE; Brumme ZL; Nanfack AJ; Quinn TC; Zolla-Pazner S; Redd AD; Finzi A; Gorny MK; Nyambi PN; Duerr R
Front Immunol; 2019; 10():1062. PubMed ID: 31139189
[TBL] [Abstract][Full Text] [Related]
19. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
[TBL] [Abstract][Full Text] [Related]
20. HIV vaccine efficacy and immune correlates of risk.
O'Connell RJ; Excler JL
Curr HIV Res; 2013 Sep; 11(6):450-63. PubMed ID: 24033301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]